Last updated: 2020-02-11 |
PUBLISHED : 11 Feb 2020 - 14:53
Tilray 10:10 pharmaceutical-grade medical cannabis oral solution, a full-spectrum extract oil, is now available for qualifying patients in Ireland.
On June 26, 2019, Ireland’s Department of Health enacted the Medical Cannabis Access Programme, which provides compassionate access to medical cannabis for patients in need in Ireland.
The new programme provides an alternative to legislation that only allows access by patients with a ministerial license, marking a significant milestone for Ireland and the global medical cannabis industry.
Access for Irish patients
The Medical Cannabis Access Programme is expected to allow patients to access Tilray‘s THC and CBD oral solutions in the second half of this year. Patients suffering from indications not covered by the programme will still have the option to obtain a ministerial licence for such products.
Tilray, a global pioneer in cannabis research, cultivation, production and distribution, announced its 10:10 THC/CBD medical cannabis oral solution has been approved for use under Ireland’s Medical Cannabis Access Program (MCAP).
The approved product is available in Ireland from United Drug Wholesale.
Under the MCAP, a consultant physician can prescribe Cannabis Based Medicinal Products, classified as Specified Controlled Drugs, for defined medical conditions. Namely:
Eligible patients must have their name entered on the Cannabis for Medical Use Register and should speak to their physician.